Epstein-Barr Virus Antibody to Nuclear Antigen, IgG
Also known as: EBV NA
Use
The Epstein-Barr Virus Antibody to Nuclear Antigen, IgG test is used to document past Epstein-Barr virus (EBV) exposure or, in conjunction with other serologic tests, to diagnose primary EBV infectious mononucleosis. Detection of EBV nuclear antigen IgG indicates past infection and is an important marker for EBV diagnosis.
Special Instructions
Parallel testing is preferred for accurate diagnosis, and convalescent specimens must be received within 30 days from receipt of the acute specimens. Specimens must be labeled as 'acute' or 'convalescent.'
Limitations
EBNA values obtained with different manufacturers' assay methods may not be used interchangeably, and the magnitude of the reported EBNA level cannot be correlated to an endpoint titer. Test results should be interpreted in conjunction with other clinical and laboratory findings. Repeated freeze-thaw cycles should be avoided to ensure specimen integrity.
FDA ApprovedNew York Approved
Methodology
Immunoassay (CLIA)
Biomarkers
LOINC Codes
- 30083-0
Result Turnaround Time
1-2 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL
Minimum Volume
0.5 mL
Container
ARUP standard transport tube
Collection Instructions
Allow specimen to clot completely at room temperature. Separate from cells ASAP or within 2 hours of collection.
Storage Instructions
Refrigerated
Causes for Rejection
Contaminated, heat-inactivated, icteric, or grossly hemolyzed specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 year |